185 related articles for article (PubMed ID: 30409442)
21. The overuse or underuse of dornase alfa.
Shah PL; Hodson ME
Curr Opin Pulm Med; 1997 Nov; 3(6):410-3. PubMed ID: 9391759
[TBL] [Abstract][Full Text] [Related]
22. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
[TBL] [Abstract][Full Text] [Related]
23. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group.
Geller DE; Eigen H; Fiel SB; Clark A; Lamarre AP; Johnson CA; Konstan MW
Pediatr Pulmonol; 1998 Feb; 25(2):83-7. PubMed ID: 9516090
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the efficacy of mucoactive aerosol therapy.
Fuloria M; Rubin BK
Respir Care; 2000 Jul; 45(7):868-73. PubMed ID: 10926385
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic Agents That Promote Airway Clearance in Hospitalized Subjects: A Systematic Review.
Sathe NA; Krishnaswami S; Andrews J; Ficzere C; McPheeters ML
Respir Care; 2015 Jul; 60(7):1061-70. PubMed ID: 25944943
[TBL] [Abstract][Full Text] [Related]
26. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
McCoy K; Hamilton S; Johnson C
Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
[TBL] [Abstract][Full Text] [Related]
27. Does the timing of inhaled dornase alfa matter?
van der Giessen L
J Cyst Fibros; 2009 Jun; 8 Suppl 1():S6-9. PubMed ID: 19460684
[TBL] [Abstract][Full Text] [Related]
28. [Novel approach to respiratory pharmacology--pharmacological basis of cough, sputum and airway clearance].
Miyata T
Yakugaku Zasshi; 2003 Dec; 123(12):987-1006. PubMed ID: 14689863
[TBL] [Abstract][Full Text] [Related]
29. Safety of ambroxol in the treatment of airway diseases in adult patients.
Cazan D; Klimek L; Sperl A; Plomer M; Kölsch S
Expert Opin Drug Saf; 2018 Dec; 17(12):1211-1224. PubMed ID: 30372367
[TBL] [Abstract][Full Text] [Related]
30. Nasally inhaled dornase alfa in the postoperative management of chronic sinusitis due to cystic fibrosis.
Raynor EM; Butler A; Guill M; Bent JP
Arch Otolaryngol Head Neck Surg; 2000 May; 126(5):581-3. PubMed ID: 10807324
[TBL] [Abstract][Full Text] [Related]
31. [Respiratory evolution of patient with mucoviscidosis treated with mucolytic agents plus dornase alfa].
Derelle J; Bertolo-Houriez E; Marchal F; Weber M; Virion JM; Vidailhet M
Arch Pediatr; 1998 Apr; 5(4):371-7. PubMed ID: 9759155
[TBL] [Abstract][Full Text] [Related]
32. Timing of dornase alfa inhalation for cystic fibrosis.
Dentice R; Elkins M
Cochrane Database Syst Rev; 2011 May; (5):CD007923. PubMed ID: 21563162
[TBL] [Abstract][Full Text] [Related]
33. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.
Bilton D; Tino G; Barker AF; Chambers DC; De Soyza A; Dupont LJ; O'Dochartaigh C; van Haren EH; Vidal LO; Welte T; Fox HG; Wu J; Charlton B;
Thorax; 2014 Dec; 69(12):1073-9. PubMed ID: 25246664
[TBL] [Abstract][Full Text] [Related]
34. Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children.
Riethmueller J; Borth-Bruhns T; Kumpf M; Vonthein R; Wiskirchen J; Stern M; Hofbeck M; Baden W
Pediatr Pulmonol; 2006 Jan; 41(1):61-6. PubMed ID: 16265663
[TBL] [Abstract][Full Text] [Related]
35. High-dose Oral Ambroxol for Early Treatment of Pulmonary Acute Respiratory Distress Syndrome: an Exploratory, Randomized, Controlled Pilot Trial.
Baranwal AK; Murthy AS; Singhi SC
J Trop Pediatr; 2015 Oct; 61(5):339-50. PubMed ID: 26130623
[TBL] [Abstract][Full Text] [Related]
36. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
[TBL] [Abstract][Full Text] [Related]
37. The pharmacologic approach to airway clearance: mucoactive agents.
Rubin BK
Paediatr Respir Rev; 2006; 7 Suppl 1():S215-9. PubMed ID: 16798570
[TBL] [Abstract][Full Text] [Related]
38. The in vitro mucolytic effect of xylitol and dornase alfa on chronic rhinosinusitis mucus.
Hardcastle T; Jain R; Radcliff F; Waldvogel-Thurlow S; Zoing M; Biswas K; Douglas R
Int Forum Allergy Rhinol; 2017 Sep; 7(9):889-896. PubMed ID: 28658521
[TBL] [Abstract][Full Text] [Related]
39. The role of dornase alfa in the treatment of cystic fibrosis.
Cramer GW; Bosso JA
Ann Pharmacother; 1996 Jun; 30(6):656-61. PubMed ID: 8792953
[TBL] [Abstract][Full Text] [Related]
40. Dornase alpha compared to hypertonic saline for lung atelectasis in critically ill patients.
Youness HA; Mathews K; Elya MK; Kinasewitz GT; Keddissi JI
J Aerosol Med Pulm Drug Deliv; 2012 Dec; 25(6):342-8. PubMed ID: 22413805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
